WHWK — Whitehawk Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1422142 ·
Last close
$3.08
Market Cap
$181.75M
52W High
$5.49
52W Low
$1.97
ADV30
376,317
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 0 | -22,943,000 | -21,209,000 | 173,686,000 | 68,973,000 | 10,529,000 |
| Jun 2026 | 0 | 0 | -18,109,000 | -16,640,000 | 193,994,000 | 85,234,000 | 11,069,000 |
| Mar 2026 | 0 | 0 | -23,522,000 | -22,194,000 | 127,231,000 | 34,790,000 | 11,056,000 |
| Dec 2025 | 0 | 0 | -24,887,000 | -23,251,000 | 150,830,000 | 37,568,000 | 14,519,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-73,644,000
Investing CF
$23,015,000
Financing CF
$81,671,000
CapEx
$-552,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.09
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-413,293,000
Inventory
$0
Receivables
$0
ST Investments
$100,699,000
EBIT TTM
$-87,825,000
Pretax Income TTM
$-83,294,000
Interest Exp TTM
$0
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-89,458,000
Free Cash Flow
$-47,464,124
Enterprise Value
$11,113,485
Total Cash
$169,672,000
Total Debt
$218,000
Shares Out
59,008,982
Trailing EPS
$-1.10
Book Value
$2.77
ROE
-52.0%
ROA
-32.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,145,000 | -114,400,000 | -20,596,000 | 150,830,000 | 14,519,000 | 136,311,000 | -97,433,000 |
| Dec 2024 | 25,983,000 | -64,820,000 | -63,691,000 | 70,319,000 | 17,841,000 | 52,478,000 | -59,550,000 |
| Dec 2023 | 24,354,000 | -71,933,000 | -65,765,000 | 132,423,000 | 27,228,000 | 105,195,000 | -59,663,000 |
| Dec 2022 | 15,216,000 | -58,957,000 | -60,513,000 | 184,237,000 | 25,859,000 | 158,378,000 | -49,640,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-79,831,000
OpCashFlow TTM
—
Assets (Latest)
$193,994,000
Forward EPS
$-1.00
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $3.13 · call volume: 2 · put volume: 1
Expected Move to 2027-01-15:
±$4.45
(142.17%) —
implied range
$-1.32 –
$7.58
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NATR | NATURES SUNSHINE PRODUCTS INC | $179.01M | $10.33 | — |
| RNAC | Cartesian Therapeutics, Inc. | $186.68M | $6.12 | — |
| ADCT | ADC Therapeutics SA | $189.89M | $1.35 | — |
| SLGL | Sol-Gel Technologies Ltd. | $172.97M | $52.83 | — |
| PYXS | Pyxis Oncology, Inc. | $172.24M | $1.44 | — |
News headlines (Yahoo Finance, 1h cache)
Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform
2026-11-12 21:05 · Yahoo
Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
2026-11-09 13:00 · Yahoo
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
2026-09-14 01:30 · Yahoo
What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?
2026-08-28 16:00 · Yahoo
Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know
2026-08-26 13:55 · Yahoo
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
2026-07-21 11:05 · Yahoo
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
2026-07-07 12:00 · Yahoo
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
2026-05-28 20:05 · Yahoo
Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?
2026-06-10 18:22 · Yahoo
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
2026-05-30 18:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.